CHI3L1-IN-5 (Compound Z17): Selective CHI3L1 Inhibition in Neuroinflammation

Executive Summary:
CHI3L1-IN-5 (Compound Z17, CAS No. 2249043-42-1) is a potent, selective small-molecule inhibitor of chitinase-3-like protein 1 (CHI3L1), a biomarker and pathogenic driver in Alzheimer’s disease (AD) and neuroinflammation (Nada et al., 2026). Compound Z17 binds CHI3L1 with a dissociation constant (KD) of 6.0 μM and demonstrates high CNS permeability (LogD7.4=2.39, PAMPA=4.6×10⁻⁶ cm/s) (product information). It blocks CHI3L1-mediated activation of the NF-κB inflammatory pathway, restoring Aβ uptake and lysosomal homeostasis in human astrocytes. Pharmacokinetic profiling reveals a human plasma half-life of 3.4 hours and minimal hERG liability (IC50>100 μM), supporting translational utility. The compound is available as a solid from APExBIO and is recommended for use in neurodegenerative and neuroinflammation assay development.

Biological Rationale

Neuroinflammation is a central, disease-driving process in Alzheimer’s disease, with reactive astrocytes and microglia releasing pro-inflammatory cytokines and neurotoxic mediators that impair synaptic function and neural viability (Nada et al., 2026). CHI3L1, also termed YKL-40, is predominantly secreted by activated astrocytes and is elevated in cerebrospinal fluid during AD progression (Nada et al., 2026). Elevated CHI3L1 correlates with cognitive decline and worsened neuropathology. Unlike enzymatic chitinases, CHI3L1 lacks catalytic activity but interacts with extracellular matrix components, modulating inflammation and tissue remodeling. Recent evidence demonstrates that CHI3L1 directly impairs amyloid-beta (Aβ) clearance by astrocytes and drives NF-κB pathway activation, promoting chronic neuroinflammation. Therefore, selective CHI3L1 inhibition represents a dual-action approach to restore astrocytic function and suppress pathogenic inflammation (internal article)—expanding beyond the classical amyloid-centric paradigm.

Mechanism of Action of CHI3L1-IN-5 (Compound Z17, CAS No. 2249043-42-1)

CHI3L1-IN-5 is a structure-activity relationship (SAR) optimized inhibitor, derived from the E14 scaffold and refined for CNS penetration and CHI3L1 selectivity (APExBIO product details). Compound Z17 binds the CHI3L1 chitinase-like fold in a 1:1 stoichiometry, achieving a dissociation constant (KD) of 6.0 μM under physiological pH and buffer conditions (Nada et al., 2026). By disrupting CHI3L1’s interaction with its protein partners, Z17 blocks downstream activation of the NF-κB inflammatory signaling cascade in human astrocytes. This results in a marked reduction in cytokine secretion (e.g., IL-1β, IL-6, TNF-α) and chemokine release, as well as normalization of lysosomal pH and proteolytic activity. Restoration of Aβ uptake and clearance by astrocytes occurs in a dose-dependent manner, supporting functional rescue of key neuroprotective mechanisms. Importantly, Z17 exhibits minimal inhibition of the cardiac hERG channel (IC50>100 μM) and is not a substrate for major CNS efflux transporters, reducing off-target and toxicity risks (APExBIO).

Evidence & Benchmarks

• Compound Z17 binds CHI3L1 with a KD of 6.0 μM (1:1 stoichiometry) as measured by isothermal titration calorimetry at 25°C, pH 7.4 (Nada et al., 2026).
• Z17 achieves CNS exposure with LogD7.4=2.39 and PAMPA permeability of 4.6×10⁻⁶ cm/s, supporting blood-brain barrier penetration (product specification).
• Pretreatment with Z17 restores Aβ uptake and lysosomal function in human iPSC-derived astrocytes exposed to CHI3L1 (dose-dependence confirmed at 1–10 μM) (Nada et al., 2026).
• Z17 blocks CHI3L1-induced activation of NF-κB and downstream cytokine secretion in vitro, reducing IL-1β, IL-6, and TNF-α by 45–65% after 24 h exposure (Nada et al., 2026).
• Pharmacokinetic data: human plasma half-life of 3.4 hours at 37°C, minimal hERG inhibition (IC50>100 μM), and low non-specific binding (APExBIO).

Applications, Limits & Misconceptions

CHI3L1-IN-5 (Compound Z17) is recommended for use in in vitro and in vivo models of neuroinflammation, specifically for dissecting roles of astrocytic CHI3L1 in Alzheimer’s disease and related neurodegenerative conditions. Its utility extends to platforms analyzing NF-κB pathway modulation, lysosomal function, and amyloid clearance. For practitioners seeking protocol guidance, see Applied Neuroinflammation Assays with CHI3L1-IN-5, which details troubleshooting and advanced workflow design; this current article expands by providing mechanistic and benchmark data from primary literature. For translational neuroinflammation research, Enabling Precision Neuroinflammation Research discusses implementation in human cell models, with this article clarifying context and molecular specificity. For practical lab guidance, Reliable CHI3L1 Inhibition for Labs reviews troubleshooting and assay design, while this piece focuses on molecular evidence and clinical rationale.

Common Pitfalls or Misconceptions

• Not a general anti-inflammatory: Z17’s effects are specific to CHI3L1-mediated pathways; it does not suppress inflammation driven by unrelated cytokines or non-CHI3L1 triggers (Nada et al., 2026).
• Not suitable for chronic solution storage: Long-term storage of Z17 in solution reduces potency; fresh preparation is recommended per product guidelines.
• Not an enzymatic chitinase inhibitor: Z17 is inactive against classical chitinases due to CHI3L1’s lack of enzymatic activity.
• Not a tauopathy modulator: No evidence supports efficacy in pure tauopathy models lacking CHI3L1 dysregulation.
• CNS exposure is model-dependent: While Z17 demonstrates favorable CNS permeability in vitro, in vivo blood-brain barrier penetration may vary across species and disease models.

Workflow Integration & Parameters

Incorporating CHI3L1-IN-5 into neurodegeneration and neuroinflammation workflows requires attention to dosing, timing, and stability. For a step-by-step protocol and troubleshooting insights, see the product page and related method guides.

Protocol Parameters

• Compound preparation: Reconstitute Z17 in DMSO (≥99.9% anhydrous) to a stock concentration of 10 mM; filter-sterilize and aliquot for single use.
• Working concentration: 1–10 μM for in vitro studies in human or rodent astrocytes; titrate according to cell type and endpoint.
• Treatment duration: Acute exposures of 12–48 hours are recommended for NF-κB inhibition and Aβ uptake assays.
• Control conditions: Always include DMSO vehicle controls and, where possible, CHI3L1-stimulated positive controls.
• Storage guidelines: Store solid Z17 at -20°C; avoid repeated freeze-thaw of solutions and use immediately after preparation (product information).
• Species compatibility: Protocols validated for human iPSC-derived and primary rodent astrocytes; cross-reactivity should be empirically determined in non-human primate or disease models.

Conclusion & Outlook

CHI3L1-IN-5 (Compound Z17) is a validated, dual-action tool compound for dissecting neuroinflammatory signaling and amyloid clearance impairment in Alzheimer’s disease models. Its specificity for CHI3L1, robust CNS permeability, and favorable pharmacokinetics—coupled with minimal off-target effects—make it a preferred choice for translational research into neurodegeneration and neuroinflammation. As highlighted in the primary reference study, Z17’s restoration of astrocyte function represents a mechanistically distinct therapeutic strategy beyond traditional amyloid-targeting agents. Ongoing research should clarify its utility in complex in vivo models and inform clinical translation. APExBIO’s provision of well-characterized, batch-verified material (C8756) supports reproducible, evidence-driven workflows for the neuroscience research community.